Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Toyama Chemical and Eisai have filed T-614's (iguratimod) marketing authorization application (MAA) as a treatment for rheumatoid arthritis.
Subscribe to our email newsletter
T-614 is a novel disease modifying anti-rheumatic drug (DMARD) originally discovered by Toyama Chemical.
Toyama Chemical and Eisai are jointly developing T-614 under a co-development and licensing deal signed in 1998.
If approved, the drug will be co-promoted by Taisho Toyama Pharmaceutical and Eisai under a two-brand, two-channel scheme.